REG - BiVictriX Therapcts. - Grant of Options

Bivictrix TherapeuticsAnnouncement

14/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211214:nRSN5119Va&default-theme=true

RNS Number : 5119V  BiVictriX Therapeutics PLC  14 December 2021

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company")

 

Grant of Options

Alderley Park, 14 December 2021 BiVictriX Therapeutics plc (AIM: BVX), an
emerging biotechnology company applying a novel approach to develop next
generation cancer therapies using insights derived from frontline clinical
experience, announces that on 13 December 2021 it granted options to employees
for an aggregate 876,333 ordinary shares of 1 pence each ("Options").

 

The Options have been granted pursuant to the terms of the Company's
Enterprise Management Incentive Scheme, which was implemented in August 2021,
in conjunction with the Company's Admission to trading on AIM.

 

All Options are subject to continuous employment and are exercisable up to 10
years from the date of being granted. The Options have an exercise price of 25
pence, this being the closing market price on 13 December 2021, and vest over
three years. Of the Options, 816,334 were granted to Oliver Schon, VP Product
Development & CMC, of which 408,167 are exercisable upon him meeting
specific R&D goals.

 

Following this grant, the total number of ordinary shares under option is
8,614,183.

 

The notifications below, made in accordance with the requirements of the
Market Abuse Regulation, provide further detail.

**Ends**

   For more information, please contact:

BiVictriX Therapeutics plc
 Tiffany Thorn, Chief Executive Officer               Email: info@bivictrix.com (mailto:info@bivictrix.com)

 Iain Ross, Chairman

                                                     Tel: +44 (0) 20 3470 0470

 SP Angel Corporate Finance LLP (NOMAD and Broker)
 David Hignell, Caroline Rowe (Corporate Finance)

 Vadim Alexandre, Rob Rees (Sales and Broking)

 Panmure Gordon (UK) Limited (Joint Broker)          Tel: +44 (0) 20 7886 2500
 Rupert Dearden/Freddy Crossley/Emma Earl

 Consilium Strategic Communications
 Ashley Tapp, Suki Virji                             Tel: +44 (0) 20 3709 5700

                           Email: Bivictrix@consilium-comms.com (mailto:Bivictrix@consilium-comms.com)

 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is
focused on leveraging clinical experience to develop a class of highly
selective, next generation cancer therapeutics which exhibit superior potency,
whilst eliminating treatment-related toxicities.

 

The Company utilises a first-in-class approach to generate a proprietary
pipeline of Bi-Cygni® therapeutics which are designed to selectively target
antigen co-expression fingerprints, or "twin antigens", on tumour cells, which
are largely absent from healthy cells. Whereas this concept has been validated
in a clinical diagnostic setting to support the diagnosis and monitoring of
haematological cancers, it has not yet been widely used in a therapeutic
setting.

 

BiVictriX has identified a diverse panel of novel cancer-specific "twin
antigens", across a broad range of cancer indications including Diffuse Large
B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic
Cell Neoplasm. The Company is using these novel "twin-antigens" to develop
more effective and safer therapeutics to target cancers that are expected to
constitute orphan indications and currently constitute areas of high unmet
medical need.

 

Find out more about BiVictriX online at www.bivictrix.com
(http://www.bivictrix.com/) .

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.

 1.    Details of the person discharging managerial responsibilities / person closely
       associated
 a)    Name                                                         Oliver Schon
 2.    Reason for the Notification
 a)    Position/status                                              VP Product Development & CMC
 b)    Initial notification/Amendment                               Initial notification
 3.    Details of the issuer, emission allowance market participant, auction
       platform, auctioneer or auction monitor
 a)    Name                                                         BiVictriX Therapeutics plc
 b)    LEI                                                          213800ZI85IZNA6N3L53
 4.    Details of the transaction(s): section to be repeated for (i) each type of
       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
       place where transactions have been conducted
 a)    Description of the Financial instrument, type of instrument  Options over Ordinary Shares of 1 pence each

                                                                    GB00BNXH3K91
       Identification code
 b)    Nature of the transactions                                   Grant of Options
 c)    Price(s) and volume(s)

Price(s)   Volume(s)

                                                                    25 pence   816,334

 d)    Aggregated information:                                      Price(s)     Volume(s)

       -   Aggregated volume

       -   Price                                                     25 pence    816,334

 
 e)    Date of the transactions                                      13 December 2021
 f)    Place of the transactions                                    Outside a trading venue

d)

Aggregated information:

-   Aggregated volume

-   Price

 Price(s)     Volume(s)

  25 pence    816,334

 

e)

Date of the transactions

 13 December 2021

f)

Place of the transactions

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHDBBDDCDBDGBX